Ligand validation:5BPS

EFO: Oligomycin A

EFO is a Ligand Of Interest in 5BPS designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
5BPS_EFO_B_102	49%	20%	0.134	0.878	2.23	1.19	16	7	0	0	100%	1
5BPS_EFO_O_101	41%	19%	0.145	0.86	2.26	1.2	11	10	1	0	100%	1
5BPS_EFO_E_101	41%	17%	0.16	0.874	2.35	1.32	14	10	0	0	100%	1
5BPS_EFO_K_101	18%	16%	0.19	0.777	2.29	1.44	15	12	1	0	100%	1
5BPS_EFO_M_101	12%	15%	0.226	0.759	2.4	1.38	13	9	2	0	100%	1
5BPS_EFO_B_101	3%	13%	0.306	0.653	2.41	1.57	14	9	1	0	100%	1
5BPS_EFO_L_101	1%	12%	0.419	0.639	2.38	1.69	12	12	2	0	100%	1
4F4S_EFO_B_102	57%	19%	0.128	0.903	2.19	1.31	12	9	1	0	100%	1
3WGV_EFO_A_2015	9%	3%	0.331	0.824	2.21	3.79	20	25	0	0	100%	1
4WQ0_EFO_A_502	2%	14%	0.406	0.664	1.43	2.37	4	25	2	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.